We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pharma Investing in Biotech to Dampen Patent Cliff Fall
Pharma Investing in Biotech to Dampen Patent Cliff Fall
Orphan drug incentives, new technology and anxiety over expiring patents have dramatically spurred investment into biotech products, with the number of large molecule, biologic drugs in development tripling over the past decade.